JOURNEY MEDICAL CORP (DERM) Stock Price & Overview

NASDAQ:DERM • US48115J1097

Current stock price

4.92 USD
-0.27 (-5.2%)
At close:
4.98 USD
+0.06 (+1.22%)
Pre-Market:

The current stock price of DERM is 4.92 USD. Today DERM is down by -5.2%. In the past month the price decreased by -28.7%. In the past year, price decreased by -34.14%.

DERM Key Statistics

52-Week Range4.31 - 9.555
Current DERM stock price positioned within its 52-week range.
1-Month Range4.31 - 7.21
Current DERM stock price positioned within its 1-month range.
Market Cap
104.944M
P/E
N/A
Fwd P/E
66.53
EPS (TTM)
-0.48
Dividend Yield
N/A

DERM Stock Performance

Today
-5.2%
1 Week
-6.46%
1 Month
-28.70%
3 Months
-43.32%
Longer-term
6 Months -34.05%
1 Year -34.14%
2 Years +33.33%
3 Years +184.39%
5 Years N/A
10 Years N/A

DERM Stock Chart

JOURNEY MEDICAL CORP / DERM Daily stock chart

DERM Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to DERM. When comparing the yearly performance of all stocks, DERM is a bad performer in the overall market: 92.71% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

DERM Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to DERM. Both the profitability and financial health of DERM have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

DERM Earnings

On March 25, 2026 DERM reported an EPS of -0.05 and a revenue of 16.08M. The company beat EPS expectations (21.57% surprise) and missed revenue expectations (-16.43% surprise).

Next Earnings DateN/A
Last Earnings DateMar 25, 2026
PeriodQ4 / 2025
EPS Reported-$0.05
Revenue Reported16.079M
EPS Surprise 21.57%
Revenue Surprise -16.43%

DERM Forecast & Estimates

10 analysts have analysed DERM and the average price target is 13.77 USD. This implies a price increase of 179.88% is expected in the next year compared to the current price of 4.92.

For the next year, analysts expect an EPS growth of 115.54% and a revenue growth 31.06% for DERM


Analysts
Analysts82
Price Target13.77 (179.88%)
EPS Next Y115.54%
Revenue Next Year31.06%

DERM Groups

Sector & Classification

DERM Financial Highlights

Over the last trailing twelve months DERM reported a non-GAAP Earnings per Share(EPS) of -0.48. The EPS increased by 53.33% compared to the year before.


Income Statements
Revenue(TTM)61.86M
Net Income(TTM)-11.43M
Industry RankSector Rank
PM (TTM) N/A
ROA -12.08%
ROE -35.89%
Debt/Equity 0.79
Chartmill High Growth Momentum
EPS Q2Q%69.33%
Sales Q2Q%18.05%
EPS 1Y (TTM)53.33%
Revenue 1Y (TTM)10.2%

DERM Ownership

Ownership
Inst Owners50.33%
Shares21.33M
Float14.25M
Ins Owners15.34%
Short Float %24.26%
Short Ratio16.19

About DERM

Company Profile

DERM logo image Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company is headquartered in Scottsdale, Arizona and currently employs 41 full-time employees. The company went IPO on 2021-11-12. The firm is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.

Company Info

IPO: 2021-11-12

JOURNEY MEDICAL CORP

9237 E Via De Ventura Blvd., Suite 105, Suite 105

Scottsdale ARIZONA 94025 US

CEO: Thomas G. Wiggans

Employees: 41

DERM Company Website

DERM Investor Relations

Phone: 14804346670

JOURNEY MEDICAL CORP / DERM FAQ

What does JOURNEY MEDICAL CORP do?

Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company is headquartered in Scottsdale, Arizona and currently employs 41 full-time employees. The company went IPO on 2021-11-12. The firm is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.


What is the stock price of JOURNEY MEDICAL CORP today?

The current stock price of DERM is 4.92 USD. The price decreased by -5.2% in the last trading session.


Does JOURNEY MEDICAL CORP pay dividends?

DERM does not pay a dividend.


How is the ChartMill rating for JOURNEY MEDICAL CORP?

DERM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the employee count for DERM stock?

JOURNEY MEDICAL CORP (DERM) currently has 41 employees.